Sijme Zeilemaker

Sijme Zeilemaker is an accomplished professional with a background in the biotechnology and pharmaceutical industry.

He holds a Master of Science degree from Leiden University.

Zeilemaker currently serves as the CEO of Immunetune and has held key positions at various renowned organizations.

Previously, he was the Head of IR & Corporate Communication, Chief Operating Officer, Senior Director Business Development, and Director Business Development at Immunicum AB (IMMU).

Prior to his tenure at Immunicum AB, Zeilemaker held roles such as the Head of Business at 2-BBB Medicines BV, Business Development Manager, Business Development Associate, and Business Intelligence Associate at BBB Therapeutics, as well as completed a Business Internship at BBB Therapeutics.

His vast experience in strategic leadership, corporate communication, business development, and operational management makes him a valuable asset in the field of biotechnology.

Zeilemaker's commitment to excellence and his proven track record of success underscore his expertise and dedication to driving innovation in the industry.